|
US4342832A
(en)
|
1979-07-05 |
1982-08-03 |
Genentech, Inc. |
Method of constructing a replicable cloning vehicle having quasi-synthetic genes
|
|
JPS5630925A
(en)
|
1979-08-21 |
1981-03-28 |
Sumitomo Chem Co Ltd |
Purification of human growth hormone
|
|
US4671958A
(en)
|
1982-03-09 |
1987-06-09 |
Cytogen Corporation |
Antibody conjugates for the delivery of compounds to target sites
|
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2, Inc., Danville, Calif. |
Geänderte antikörper.
|
|
US6710169B2
(en)
|
1987-10-02 |
2004-03-23 |
Genentech, Inc. |
Adheson variants
|
|
US4952394A
(en)
|
1987-11-23 |
1990-08-28 |
Bristol-Myers Company |
Drug-monoclonal antibody conjugates
|
|
US5981485A
(en)
|
1997-07-14 |
1999-11-09 |
Genentech, Inc. |
Human growth hormone aqueous formulation
|
|
US5681566A
(en)
|
1988-10-24 |
1997-10-28 |
3I Research Exploitation Limited |
Antibody conjugates with two or more covalently linked FC regions
|
|
GB8824869D0
(en)
|
1988-10-24 |
1988-11-30 |
Stevenson G T |
Synthetic antibody
|
|
US5225538A
(en)
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
CS89491A3
(en)
|
1990-04-09 |
1992-01-15 |
Chugai Pharmaceutical Co Ltd |
Hybrid calcitonin
|
|
RU2145233C1
(ru)
*
|
1990-07-02 |
2000-02-10 |
Дзе Аризона Борд оф Риджентс |
Неупорядоченная библиотека пептидов, способ ее получения и способ идентификации пептида, синтезированного твердофазным синтезом
|
|
WO1992021029A1
(en)
|
1991-05-10 |
1992-11-26 |
Genentech, Inc. |
Selecting ligand agonists and antagonists
|
|
US6329509B1
(en)
|
1991-08-14 |
2001-12-11 |
Genentech, Inc. |
Anti-IgE antibodies
|
|
PT618807E
(pt)
|
1991-12-20 |
2003-03-31 |
Novo Nordisk As |
Formulacao farmaceutica estabilizada compreendendo a hormona de crescimento humano e a histidina
|
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
|
DK0563475T3
(da)
|
1992-03-25 |
2000-09-18 |
Immunogen Inc |
Konjugater af cellebindende midler og derivater af CC-1065
|
|
US5686072A
(en)
|
1992-06-17 |
1997-11-11 |
Board Of Regents, The University Of Texas |
Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
|
|
US6284727B1
(en)
|
1993-04-07 |
2001-09-04 |
Scios, Inc. |
Prolonged delivery of peptides
|
|
US5359030A
(en)
|
1993-05-10 |
1994-10-25 |
Protein Delivery, Inc. |
Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
|
|
US5484892A
(en)
|
1993-05-21 |
1996-01-16 |
Dana-Farber Cancer Institute, Inc. |
Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
|
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
AU3272695A
(en)
|
1994-08-12 |
1996-03-07 |
Immunomedics Inc. |
Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5698672A
(en)
|
1995-04-04 |
1997-12-16 |
Zymogenetics, Inc. |
Synthetic calcitonin mimetics
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
JP3871713B2
(ja)
|
1995-05-10 |
2007-01-24 |
協和醗酵工業株式会社 |
新規毒素複合体
|
|
AU706056B2
(en)
|
1995-10-13 |
1999-06-10 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Immunotoxin containing a disulfide-stabilized antibody fragment
|
|
DE69729283T2
(de)
|
1996-03-20 |
2005-05-25 |
Immunomedics, Inc. |
GLYKOSYLIERTE IgG ANTIKÖRPER
|
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
US6653104B2
(en)
|
1996-10-17 |
2003-11-25 |
Immunomedics, Inc. |
Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
|
|
EP1629849B2
(en)
|
1997-01-07 |
2017-10-04 |
Amylin Pharmaceuticals, LLC |
Pharmaceutical compositions comprising exendins and agonists thereof
|
|
US6548644B1
(en)
|
1997-03-10 |
2003-04-15 |
Immunex Corporation |
Site protected protein modification
|
|
ATE383430T1
(de)
|
1997-03-20 |
2008-01-15 |
Us Gov Health & Human Serv |
Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
|
|
US6183744B1
(en)
|
1997-03-24 |
2001-02-06 |
Immunomedics, Inc. |
Immunotherapy of B-cell malignancies using anti-CD22 antibodies
|
|
CA2283834A1
(en)
|
1997-03-31 |
1998-10-08 |
James Arthur Hoffmann |
Glucagon-like peptide-1 analogs
|
|
ES2297889T3
(es)
|
1997-07-14 |
2008-05-01 |
Bolder Biotechnology, Inc. |
Derivados de hormona de crecimiento y proteinas relacionadas.
|
|
WO1999043708A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
US6576744B1
(en)
|
1998-09-23 |
2003-06-10 |
Zymogenetics, Inc. |
Cytokine receptor zalpha11
|
|
US6803451B2
(en)
|
1998-09-23 |
2004-10-12 |
Zymogenetics, Inc. |
Cytokine receptor zalpha11 polypeptides
|
|
US7488590B2
(en)
|
1998-10-23 |
2009-02-10 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
US7425541B2
(en)
|
1998-12-11 |
2008-09-16 |
Medarex, Inc. |
Enzyme-cleavable prodrug compounds
|
|
EP2364997A3
(en)
|
1999-01-15 |
2012-07-04 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US6897044B1
(en)
|
1999-01-28 |
2005-05-24 |
Biogen Idec, Inc. |
Production of tetravalent antibodies
|
|
US7258869B1
(en)
|
1999-02-08 |
2007-08-21 |
Alza Corporation |
Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
|
|
US6307024B1
(en)
|
1999-03-09 |
2001-10-23 |
Zymogenetics, Inc. |
Cytokine zalpha11 Ligand
|
|
US6395226B1
(en)
|
1999-04-06 |
2002-05-28 |
Medtronic, Inc. |
Alkoxysilane/alkysilane copolymer coating of medical devices
|
|
DE19926475A1
(de)
|
1999-06-10 |
2000-12-14 |
Ktb Tumorforschungs Gmbh |
Träger-Pharmaka-Konjugate
|
|
EP2289549A3
(en)
|
1999-10-01 |
2011-06-15 |
Immunogen, Inc. |
Immunoconjugates for treating cancer
|
|
US6824780B1
(en)
|
1999-10-29 |
2004-11-30 |
Genentech, Inc. |
Anti-tumor antibody compositions and methods of use
|
|
ATE458814T1
(de)
|
1999-12-03 |
2010-03-15 |
Zymogenetics Inc |
Menschliches zytokinrezeptor
|
|
CA2400034A1
(en)
|
2000-02-17 |
2001-08-23 |
Incyte Genomics, Inc. |
Human kinases
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
US6570040B2
(en)
|
2000-03-16 |
2003-05-27 |
The Regents Of The University Of California |
Chemoselective ligation
|
|
ES2339959T3
(es)
|
2000-04-05 |
2010-05-27 |
Zymogenetics, Inc. |
Receptores de citoquina zalza11 solubles.
|
|
US6756480B2
(en)
|
2000-04-27 |
2004-06-29 |
Amgen Inc. |
Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
|
|
WO2001083448A2
(de)
|
2000-05-02 |
2001-11-08 |
Tietze Lutz F |
Neue prodrugs von 6-hydroxy-2,3-dihydro-1h-indolen, 5-hydroxy-1,2-dihydro-3h-pyrrolo[3,2-e]indolen und 5-hydroxy-1,2-dihydro-3h-benzo[e]indolen sowie von 6-hydroxy-1,2,3,4-tetrahydro-benzo[f]chinolin-derivaten für eine selektive krebstherapie
|
|
CA2409991A1
(en)
|
2000-05-24 |
2001-11-29 |
Imclone Systems Incorporated |
Bispecific immunoglobulin-like antigen binding proteins and method of production
|
|
CA2413149A1
(en)
|
2000-06-14 |
2001-12-20 |
Medarex, Inc. |
Prodrug compounds with isoleucine
|
|
AU2001275525B2
(en)
|
2000-06-14 |
2007-04-26 |
Medarex, Inc. |
Tripeptide prodrug compounds
|
|
EP1337636B1
(en)
|
2000-08-08 |
2006-10-18 |
ZymoGenetics, Inc. |
Soluble zcytor 11 cytokine receptors
|
|
WO2002015700A1
(en)
|
2000-08-24 |
2002-02-28 |
Coulter Pharmaceutical, Inc. |
Prodrugs activated by plasmin and their use in cancer chemotherapy
|
|
US7118737B2
(en)
|
2000-09-08 |
2006-10-10 |
Amylin Pharmaceuticals, Inc. |
Polymer-modified synthetic proteins
|
|
US20020128448A1
(en)
*
|
2000-10-20 |
2002-09-12 |
Idec Pharmaceuticals Corporation |
Variant IgG3 Rituxan and therapeutic use thereof
|
|
CA2428242A1
(en)
|
2000-11-07 |
2002-05-16 |
Zymogenetics, Inc. |
Human tumor necrosis factor receptor
|
|
GB0029154D0
(en)
|
2000-11-30 |
2001-01-17 |
Lee Helen |
Signal enhancement with multiple labelled-antibodies
|
|
DK1724284T3
(da)
|
2000-12-07 |
2009-11-02 |
Lilly Co Eli |
GLP-1 fusionsproteiner
|
|
EP1370676A4
(en)
|
2001-03-02 |
2004-09-22 |
Zymogenetics Inc |
CYTOKIN RECEPTOR FROM MOUSE
|
|
CA2441484A1
(en)
|
2001-03-23 |
2002-10-03 |
Napro Biotherapeutics, Inc. |
Molecular conjugates for use in treatment of cancer
|
|
AU2002252460A1
(en)
|
2001-03-27 |
2002-10-08 |
Zymogenetics, Inc. |
Human cytokine receptor
|
|
JP2005502322A
(ja)
|
2001-04-19 |
2005-01-27 |
ザ スクリップス リサーチ インスティテュート |
非天然アミノ酸のインビボ組込み
|
|
US7256257B2
(en)
|
2001-04-30 |
2007-08-14 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
US6608196B2
(en)
|
2001-05-03 |
2003-08-19 |
Galileo Pharmaceuticals, Inc. |
Process for solid supported synthesis of pyruvate-derived compounds
|
|
DE60228954D1
(en)
|
2001-05-03 |
2008-10-30 |
Galileo Lab Inc |
Pyruvatderivate
|
|
US20030103985A1
(en)
|
2001-05-18 |
2003-06-05 |
Boehringer Ingelheim International Gmbh |
Cytotoxic CD44 antibody immunoconjugates
|
|
US6978243B2
(en)
|
2001-05-22 |
2005-12-20 |
International Flavors & Fragrances Inc. |
Method for the analysis of sensory perception
|
|
PL403488A1
(pl)
|
2001-05-24 |
2013-07-08 |
Zymogenetics, Inc. |
Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
|
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
|
KR20030033007A
(ko)
|
2001-05-31 |
2003-04-26 |
코울터 파머수티컬, 인코포레이티드 |
세포독소, 약물전구체, 링커 및 이에 유용한 안정화제
|
|
IL158969A0
(en)
|
2001-06-01 |
2004-05-12 |
Cornell Res Foundation Inc |
Modified antibodies to prostate-specific membrane antigen and uses thereof
|
|
US7803915B2
(en)
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
|
US7321026B2
(en)
|
2001-06-27 |
2008-01-22 |
Skytech Technology Limited |
Framework-patched immunoglobulins
|
|
US7176278B2
(en)
|
2001-08-30 |
2007-02-13 |
Biorexis Technology, Inc. |
Modified transferrin fusion proteins
|
|
US6770625B2
(en)
|
2001-09-07 |
2004-08-03 |
Nobex Corporation |
Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
|
|
US20030109682A1
(en)
|
2001-09-07 |
2003-06-12 |
Daniel Santi |
Maytansines and maytansine conjugates
|
|
US7091186B2
(en)
|
2001-09-24 |
2006-08-15 |
Seattle Genetics, Inc. |
p-Amidobenzylethers in drug delivery agents
|
|
ES2342929T3
(es)
|
2001-09-26 |
2010-07-19 |
The Government of the United States of America as represented by the Secretary of Health and Human |
Anticuerpos anti-cd22 con afinidad aumentada por las celulas leucemicas que expresan cd22.
|
|
US6864069B2
(en)
|
2001-10-05 |
2005-03-08 |
Bayer Pharmaceuticals Corporation |
Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
|
|
EP2305311A3
(en)
|
2001-10-10 |
2011-07-20 |
BioGeneriX AG |
Glycoconjugation of peptides
|
|
MXPA04003798A
(es)
|
2001-10-25 |
2004-07-30 |
Genentech Inc |
Composiciones de glicoproteina.
|
|
US20030171285A1
(en)
|
2001-11-20 |
2003-09-11 |
Finn Rory F. |
Chemically-modified human growth hormone conjugates
|
|
EP2277888A3
(en)
|
2001-12-21 |
2011-04-27 |
Human Genome Sciences, Inc. |
Fusion proteins of albumin and erythropoietin
|
|
US6716821B2
(en)
|
2001-12-21 |
2004-04-06 |
Immunogen Inc. |
Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
|
|
GB0130947D0
(en)
|
2001-12-24 |
2002-02-13 |
Lee Helen |
Improved sample preparation for the detection of infectious agents
|
|
JP2005526044A
(ja)
|
2002-02-21 |
2005-09-02 |
デューク ユニバーシティ |
抗ｃｄ２２抗体を使用した治療方法
|
|
US20080152649A1
(en)
|
2002-03-01 |
2008-06-26 |
Xencor, Inc. |
Optimized igf-1r antibodies and methods of using the same
|
|
US20090042291A1
(en)
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20100311954A1
(en)
|
2002-03-01 |
2010-12-09 |
Xencor, Inc. |
Optimized Proteins that Target Ep-CAM
|
|
US20080206242A1
(en)
|
2002-03-01 |
2008-08-28 |
Xencor, Inc. |
Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies
|
|
US7657380B2
(en)
|
2003-12-04 |
2010-02-02 |
Xencor, Inc. |
Methods of generating variant antibodies with increased host string content
|
|
US20070148171A1
(en)
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20080254027A1
(en)
|
2002-03-01 |
2008-10-16 |
Bernett Matthew J |
Optimized CD5 antibodies and methods of using the same
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US20080199471A1
(en)
|
2002-03-01 |
2008-08-21 |
Bernett Matthew J |
Optimized cd40 antibodies and methods of using the same
|
|
AU2003217912A1
(en)
|
2002-03-01 |
2003-09-16 |
Xencor |
Antibody optimization
|
|
US20090162382A1
(en)
|
2002-03-01 |
2009-06-25 |
Bernett Matthew J |
Optimized ca9 antibodies and methods of using the same
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
JP4477881B2
(ja)
|
2002-03-01 |
2010-06-09 |
ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド |
治療剤または細胞毒性剤と生物活性ペプチドとの抱合体
|
|
US20080260731A1
(en)
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
|
US20080219974A1
(en)
|
2002-03-01 |
2008-09-11 |
Bernett Matthew J |
Optimized antibodies that target hm1.24
|
|
US6756397B2
(en)
|
2002-04-05 |
2004-06-29 |
Immunogen, Inc. |
Prodrugs of CC-1065 analogs
|
|
GB0210121D0
(en)
|
2002-05-02 |
2002-06-12 |
Celltech R&D Ltd |
Biological products
|
|
BR0311471A
(pt)
|
2002-05-30 |
2007-04-27 |
Macrogenics Inc |
anticorpo anti-cd16a, e, métodos de redução de uma resposta imune deletéria em um mamìfero e de tratamento de uma resposta imune deletéria em um mamìfero
|
|
WO2003105782A2
(en)
|
2002-06-17 |
2003-12-24 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Specificity grafting of a murine antibody onto a human framework
|
|
SI1545613T1
(sl)
|
2002-07-31 |
2011-11-30 |
Seattle Genetics Inc |
Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
|
|
EP1542723B1
(en)
|
2002-08-16 |
2011-02-23 |
ImmunoGen, Inc. |
Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
|
|
US7189811B2
(en)
|
2002-09-06 |
2007-03-13 |
National Institute Of Immunology |
Process for solubilization of recombinant proteins expressed as inclusion body
|
|
US20060235208A1
(en)
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
DE60329700D1
(en)
|
2002-10-16 |
2009-11-26 |
Scripps Research Inst |
Glycoproteinsynthese
|
|
US7534427B2
(en)
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
|
JP2006524039A
(ja)
|
2003-01-09 |
2006-10-26 |
マクロジェニクス，インコーポレーテッド |
変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
|
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
US7112439B2
(en)
|
2003-01-09 |
2006-09-26 |
Macrogenics, Inc. |
Dual expression vector system for antibody expression in bacterial and mammalian cells
|
|
CN101444621B
(zh)
|
2003-02-11 |
2013-11-20 |
夏尔人类遗传性治疗公司 |
使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
|
|
EP2289559B1
(en)
|
2003-02-20 |
2014-02-12 |
Seattle Genetics, Inc. |
Anit-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
US20070275460A1
(en)
|
2003-03-03 |
2007-11-29 |
Xencor.Inc. |
Fc Variants With Optimized Fc Receptor Binding Properties
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US20070041987A1
(en)
|
2003-03-19 |
2007-02-22 |
Daniel Carter |
Fragments or polymers of albumin with tunable vascular residence time for use in therapeutic delivery and vaccine development
|
|
US20050281829A1
(en)
|
2003-05-06 |
2005-12-22 |
Hehir Cristina A T |
Fc chimeric proteins with anti-HIV drugs
|
|
EP3002012A1
(en)
|
2003-05-06 |
2016-04-06 |
Biogen Hemophilia Inc. |
Clotting factor-fc chimeric proteins to treat hemophilia
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
EA009285B1
(ru)
|
2003-05-14 |
2007-12-28 |
Иммуноджен, Инк. |
Композиция конъюгированного лекарственного средства
|
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
|
MXPA05013565A
(es)
|
2003-06-12 |
2006-03-09 |
Lilly Co Eli |
Proteinas de fusion analogas al glp-1.
|
|
US7888063B2
(en)
|
2003-06-18 |
2011-02-15 |
The Scripps Research Institute |
Unnatural reactive amino acid genetic code additions
|
|
JP5091476B2
(ja)
|
2003-06-27 |
2012-12-05 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用
|
|
ATE496944T1
(de)
*
|
2003-07-21 |
2011-02-15 |
Immunogen Inc |
Ca6-antigenspezifisches zytotoxisches konjugat und verfahren zu dessen anwendung
|
|
US6943234B2
(en)
|
2003-07-30 |
2005-09-13 |
Zymogenetics, Inc. |
Pichia methanolica secretory signal
|
|
US20070148170A1
(en)
|
2005-10-03 |
2007-06-28 |
Desjarlais John R |
Fc Variants With Optimized Fc Receptor Binding Properties
|
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
|
US20060134105A1
(en)
|
2004-10-21 |
2006-06-22 |
Xencor, Inc. |
IgG immunoglobulin variants with optimized effector function
|
|
MXPA06003553A
(es)
|
2003-09-30 |
2007-02-02 |
Sterrenbeld Biotechnologie North America Inc |
Un proceso para producir proteina exogena en la leche de mamiferos transgenicos y un proceso para purificar proteinas de la leche.
|
|
EP2322569B1
(en)
|
2003-10-09 |
2020-08-26 |
Ambrx, Inc. |
Polymer derivatives for the selective modification of proteins
|
|
DK1725249T3
(en)
|
2003-11-06 |
2014-03-17 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugating to ligands.
|
|
EP2239273B1
(en)
|
2003-11-13 |
2013-10-09 |
Hanmi Science Co., Ltd. |
A pharmaceutical composition comprosing an immunoglobulin fc as a carrier
|
|
JP4813364B2
(ja)
|
2003-11-25 |
2011-11-09 |
アメリカ合衆国 |
突然変異型抗ｃｄ２２抗体および免疫複合体
|
|
EP1701979A2
(en)
|
2003-12-03 |
2006-09-20 |
Xencor, Inc. |
Optimized antibodies that target the epidermal growth factor receptor
|
|
CN101665538A
(zh)
|
2003-12-18 |
2010-03-10 |
诺沃挪第克公司 |
与白蛋白样物质相连的新glp-1类似物
|
|
EP1697520A2
(en)
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
|
GB2426521A
(en)
|
2004-02-02 |
2006-11-29 |
Ambrx Inc |
Modified human four helical bundle polypeptides and their uses
|
|
AU2005319099B2
(en)
|
2004-02-02 |
2010-09-16 |
Ambrx, Inc. |
Modified human growth hormone
|
|
US7422696B2
(en)
|
2004-02-20 |
2008-09-09 |
Northwestern University |
Multicomponent nanorods
|
|
JP5064037B2
(ja)
|
2004-02-23 |
2012-10-31 |
ジェネンテック， インコーポレイテッド |
複素環式自壊的リンカーおよび結合体
|
|
WO2006074418A2
(en)
|
2005-01-07 |
2006-07-13 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
|
WO2005084390A2
(en)
|
2004-03-02 |
2005-09-15 |
Seattle Genetics, Inc. |
Partially loaded antibodies and methods of their conjugation
|
|
AU2005227326B2
(en)
|
2004-03-24 |
2009-12-03 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
|
US20050260711A1
(en)
|
2004-03-30 |
2005-11-24 |
Deepshikha Datta |
Modulating pH-sensitive binding using non-natural amino acids
|
|
US7662936B2
(en)
|
2004-04-07 |
2010-02-16 |
Genentech, Inc. |
Mass spectrometry of antibody conjugates
|
|
MXPA06012601A
(es)
|
2004-05-10 |
2007-05-10 |
Macrogenics Inc |
Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos.
|
|
RU2402548C2
(ru)
|
2004-05-19 |
2010-10-27 |
Медарекс, Инк. |
Химические линкеры и их конъюгаты
|
|
BRPI0510909A2
(pt)
|
2004-05-19 |
2008-12-16 |
Medarex Inc |
composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor
|
|
CN114053429A
(zh)
|
2004-06-01 |
2022-02-18 |
健泰科生物技术公司 |
抗体-药物偶联物和方法
|
|
MXPA06014684A
(es)
|
2004-06-18 |
2007-02-12 |
Ambrx Inc |
Novedosos polipeptidos de enlace antigeno y sus usos.
|
|
WO2006091231A2
(en)
|
2004-07-21 |
2006-08-31 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
|
US7126393B2
(en)
|
2004-08-20 |
2006-10-24 |
Micron Technology, Inc. |
Delay circuit with reset-based forward path static delay
|
|
WO2006031825A2
(en)
|
2004-09-13 |
2006-03-23 |
Macrogenics, Inc. |
Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof
|
|
ES2579805T3
(es)
|
2004-09-23 |
2016-08-16 |
Genentech, Inc. |
Anticuerpos y conjugados modificados por ingeniería genética con cisteína
|
|
BRPI0516011A
(pt)
*
|
2004-09-24 |
2008-08-19 |
Amgen Inc |
moléculas fc modificadas
|
|
CA2565209A1
(en)
|
2004-11-09 |
2006-05-18 |
Usv Limited |
A novel process for purification of human growth harmone
|
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
JP4652414B2
(ja)
|
2004-11-12 |
2011-03-16 |
ゼンコー・インコーポレイテッド |
ＦｃＲｎとの変化した結合を有するＦｃ変異体
|
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US20070135620A1
(en)
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US7255012B2
(en)
|
2004-12-01 |
2007-08-14 |
Rosemount Inc. |
Process fluid flow device with variable orifice
|
|
ZA200704927B
(en)
|
2004-12-22 |
2009-09-30 |
Ambrx Inc |
Compositions of aminoacyl-tRNA synthetase and uses thereof
|
|
CA2590590C
(en)
|
2004-12-22 |
2016-04-19 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
|
AU2005323106B2
(en)
|
2004-12-22 |
2010-07-29 |
Ambrx, Inc. |
Methods for expression and purification of recombinant human growth hormone
|
|
AU2005322019B2
(en)
|
2004-12-22 |
2010-08-26 |
Ambrx, Inc. |
Formulations of human growth hormone comprising a non-naturally encoded amino acid
|
|
JP5165387B2
(ja)
|
2005-02-11 |
2013-03-21 |
イムノゲン インコーポレーティッド |
安定な薬物複合体を調製するための方法
|
|
US7466406B2
(en)
|
2005-03-14 |
2008-12-16 |
Northwestern University |
Analyte detection using nanowires produced by on-wire lithography
|
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
|
ES2707152T3
(es)
|
2005-04-15 |
2019-04-02 |
Macrogenics Inc |
Diacuerpos covalentes y usos de los mismos
|
|
US20080227205A1
(en)
|
2005-06-03 |
2008-09-18 |
Ambrx, Inc. |
Incorporation on Non-Naturally Encoded Amino Acids Into Proteins
|
|
CN103030690A
(zh)
|
2005-06-03 |
2013-04-10 |
Ambrx公司 |
经改良人类干扰素分子和其用途
|
|
JP2007037018A
(ja)
|
2005-07-29 |
2007-02-08 |
Nec Electronics Corp |
スイッチ回路
|
|
SI1919503T1
(sl)
|
2005-08-10 |
2015-02-27 |
Macrogenics, Inc. |
Identifikacija in inĺ˝eniring protiteles z variantnimi fc regijami in postopki za njih uporabo
|
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
|
AU2005335491B2
(en)
|
2005-08-18 |
2010-11-25 |
Ambrx, Inc. |
Compositions of tRNA and uses thereof
|
|
CA2630415A1
(en)
|
2005-10-20 |
2007-04-26 |
The Scripps Research Institute |
Fc labeling for immunostaining and immunotargeting
|
|
JP5116686B2
(ja)
|
2005-10-26 |
2013-01-09 |
メダレックス インコーポレイテッド |
Ｃｃ−１０６５類似体の調製方法及び調製用化合物
|
|
AU2006311938A1
(en)
|
2005-11-02 |
2007-05-18 |
Ambrx, Inc. |
Biosynthetic polypeptide fusion inhibitors
|
|
PL1954710T3
(pl)
|
2005-11-08 |
2011-09-30 |
Ambrx Inc |
Przyspieszacze do modyfikacji aminokwasów niewystępujących w przyrodzie i polipeptydów zbudowanych z aminokwasów nie występujących w przyrodzie
|
|
ES2547554T3
(es)
|
2005-11-16 |
2015-10-07 |
Ambrx, Inc. |
Métodos y composiciones que comprenden aminoácidos no naturales
|
|
KR101423898B1
(ko)
|
2005-12-14 |
2014-07-28 |
암브룩스, 인코포레이티드 |
비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비-천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비-천연 아미노산 및 폴리펩티드의 용도
|
|
JP2009522275A
(ja)
|
2005-12-30 |
2009-06-11 |
アンブルックス，インコーポレイテッド |
非天然アミノ酸およびポリペプチドを含んでいる組成物、それらに関する方法、ならびに、それらの使用
|
|
EP1974025A4
(en)
|
2006-01-19 |
2009-03-11 |
Ambrx Inc |
NON-NATURAL AMINO ACID POLYPEPTIDES WITH MODULATED IMMUNOGENICITY
|
|
US20070198996A1
(en)
|
2006-02-09 |
2007-08-23 |
Ziep Software Inc. |
System and method for driving peripheral devices
|
|
EP1987058B1
(en)
|
2006-02-10 |
2010-05-12 |
ZymoGenetics, Inc. |
Soluble il-17rcx4 and methods of using in inflammation
|
|
US7750116B1
(en)
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
|
JP2009532336A
(ja)
|
2006-03-06 |
2009-09-10 |
メディミューン，エルエルシー |
ヒト化抗ｃｄ２２抗体、並びに腫瘍、移植及び自己免疫疾患の治療におけるこれらの使用
|
|
JP2009529331A
(ja)
|
2006-03-10 |
2009-08-20 |
マクロジェニクス，インコーポレーテッド |
変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法
|
|
EP2021029B1
(en)
|
2006-05-26 |
2014-06-11 |
MacroGenics, Inc. |
Humanized fc gamma riib-specific antibodies and methods of use thereof
|
|
JP2009538629A
(ja)
|
2006-05-30 |
2009-11-12 |
ジェネンテック・インコーポレーテッド |
抗体およびイムノコンジュゲートとこれらの使用方法
|
|
CN100388056C
(zh)
|
2006-06-02 |
2008-05-14 |
上海微电子装备有限公司 |
一种投影物镜光学系统
|
|
SI2029173T1
(sl)
|
2006-06-26 |
2016-12-30 |
Macrogenics, Inc. |
Protitelesa, specifična za Fc RIIB, in postopki za njihovo uporabo
|
|
AU2007275294A1
(en)
|
2006-07-18 |
2008-01-24 |
Centocor, Inc. |
Human GLP-1 mimetibodies, compositions, methods and uses
|
|
MX2009002460A
(es)
|
2006-09-08 |
2009-03-20 |
Ambrx Inc |
Arnt supresor hibrido para celulas de vertebrados.
|
|
ES2465473T3
(es)
|
2006-09-08 |
2014-06-05 |
Ambrx, Inc. |
Transcripción de arnt supresor en células de vertebrado
|
|
KR20090060294A
(ko)
|
2006-09-08 |
2009-06-11 |
암브룩스, 인코포레이티드 |
변형된 인간 혈장 폴리펩티드 또는 Ｆｃ 스캐폴드 및 그의 용도
|
|
KR20090057072A
(ko)
|
2006-09-08 |
2009-06-03 |
암브룩스, 인코포레이티드 |
척추동물 세포에 의한 비천연 아미노산의 부위 특이적 도입
|
|
US7985783B2
(en)
|
2006-09-21 |
2011-07-26 |
The Regents Of The University Of California |
Aldehyde tags, uses thereof in site-specific protein modification
|
|
US20080112961A1
(en)
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
|
US7476555B2
(en)
|
2006-11-15 |
2009-01-13 |
Airdio Wireless Inc. |
Method of chip manufacturing
|
|
CA2671457C
(en)
|
2006-12-01 |
2017-09-26 |
Medarex, Inc. |
Human antibodies that bind cd22 and uses thereof
|
|
WO2008140603A2
(en)
|
2006-12-08 |
2008-11-20 |
Macrogenics, Inc. |
METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
|
|
MX2009006617A
(es)
|
2006-12-18 |
2009-07-24 |
Ambrx Inc |
Composiciones que contienen, metodos que involucran y usos de aminoacidos y polipeptidos no naturales.
|
|
JP4467557B2
(ja)
|
2006-12-25 |
2010-05-26 |
富士通株式会社 |
光スイッチング方法及び光スイッチ
|
|
AU2007341997A1
(en)
|
2006-12-28 |
2008-07-10 |
Ambrx, Inc. |
Phenazine and quinoxaline substituted amino acids and polypeptides
|
|
JP5163642B2
(ja)
*
|
2007-03-29 |
2013-03-13 |
コニカミノルタホールディングス株式会社 |
有機エレクトロルミネセンス素子
|
|
US20080244222A1
(en)
|
2007-03-30 |
2008-10-02 |
Intel Corporation |
Many-core processing using virtual processors
|
|
KR20140012199A
(ko)
|
2007-03-30 |
2014-01-29 |
암브룩스, 인코포레이티드 |
변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
|
|
JP2010525821A
(ja)
|
2007-05-02 |
2010-07-29 |
アンブルックス，インコーポレイテッド |
修飾ＩＦＮβポリペプチドおよびこれらの使用
|
|
CL2008001334A1
(es)
|
2007-05-08 |
2008-09-22 |
Genentech Inc |
Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
|
|
WO2008150494A1
(en)
|
2007-05-30 |
2008-12-11 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
|
KR20100047844A
(ko)
|
2007-06-20 |
2010-05-10 |
노쓰웨스턴유니버시티 |
나노물질 및 중합체를 함유하는 조성물의 패턴화
|
|
EA201000343A1
(ru)
|
2007-10-04 |
2011-10-31 |
Займодженетикс, Инк. |
ЧЛЕН СЕМЕЙСТВА B7, zB7H6 И РОДСТВЕННЫЕ КОМПОЗИЦИИ И СПОСОБЫ
|
|
US8795667B2
(en)
|
2007-12-19 |
2014-08-05 |
Macrogenics, Inc. |
Compositions for the prevention and treatment of smallpox
|
|
US7722865B2
(en)
|
2008-01-18 |
2010-05-25 |
Biomarin Pharmaceutical Inc. |
Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
|
|
WO2009120611A2
(en)
|
2008-03-27 |
2009-10-01 |
The Regents Of The University Of California |
Aldehyde tags, uses thereof in site-specific protein modification
|
|
US8591889B2
(en)
|
2008-04-04 |
2013-11-26 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Human monoclonal antibodies specific for CD22
|
|
AU2009262199B2
(en)
*
|
2008-06-27 |
2012-08-09 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
|
JP2012509663A
(ja)
|
2008-11-21 |
2012-04-26 |
コーニング インコーポレイテッド |
細胞培養のための、突起間隔を開けた基板および装置
|
|
WO2010096394A2
(en)
*
|
2009-02-17 |
2010-08-26 |
Redwood Biosciences, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
|
CA2824143C
(en)
|
2011-01-14 |
2018-12-18 |
Redwood Bioscience, Inc. |
Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
|
|
US9310374B2
(en)
|
2012-11-16 |
2016-04-12 |
Redwood Bioscience, Inc. |
Hydrazinyl-indole compounds and methods for producing a conjugate
|
|
EP3074010B1
(en)
|
2013-11-27 |
2025-05-14 |
Redwood Bioscience, Inc. |
Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
|
|
CN106456608B
(zh)
|
2014-06-06 |
2020-08-28 |
雷德伍德生物科技股份有限公司 |
抗her2抗体-美登木素缀合物及其使用方法
|